• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1267494 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type: ]5 p6 P  h( ], W- G" ^
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 3 @7 S# T* K4 M% A) w0 [
+ Author Affiliations
8 ]6 R/ l  F8 K) m- A4 n$ p
: z+ k+ k( y) H" K: I/ _3 u1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
" w1 H% e1 p3 M: f+ K2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
1 g# d' V# P; o, p/ l6 X3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ m9 Q. t2 r* h- `: Q7 M4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan # r. t& N; P$ d; Q- \, d1 C
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 7 _( b# ~. {1 n7 j3 C  U
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 5 p7 ~; i" Q/ ?0 W4 e4 g
7Kinki University School of Medicine, Osaka 589-8511, Japan
. H1 i( X, H( |+ ?# a8Izumi Municipal Hospital, Osaka 594-0071, Japan ! K; K3 n6 V/ H. }
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
/ H: u& {  y1 |6 r& i9 RCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; k9 |; F5 d( T0 X
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. / x. u" T( T! p7 }& m- P

- o* V0 p+ P  V2 q
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
/ ~/ E! p$ h1 L( J
( z- u5 G% o1 H: `$ w5 OAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato - {5 k, r& }; b$ x  w. T
$ t+ r& E/ ], V" ]* e  C1 n5 O% M
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
9 C$ o' H8 C8 W3 m5 R# c, c
" I" [1 G' |# O( qPublished online on: Thursday, December 1, 2011
9 S9 l, |0 ^- T1 F0 I7 }+ T- b3 U: s
Doi: 10.3892/ol.2011.507
1 N$ j: ^3 J, e" }2 t7 m* {. O9 {  l8 ?' w
Pages: 405-410 % D1 E5 ^+ y1 \2 Q% }

+ x% m5 ]- ~( MAbstract:
8 t) Y. G# [# ?) A1 A. l; vS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.% [- C5 g% C6 k

: p2 F( G3 C* G# N0 R. V: W( u
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
( L4 A: P5 A. v" U- AF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 + l; G8 G. X6 e
+ Author Affiliations
* N1 P' ]. X9 z  t0 \1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu + E7 n6 w6 \7 q. w
2Department of Thoracic Surgery, Kyoto University, Kyoto - ?# i! A! T4 e; J- Z: A
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 9 z( k0 Q; C( ^
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp ( s5 n  Z( U2 p# h
Received September 3, 2010. " N6 s* J; J; P# S- _, p2 l' w3 ]
Revision received November 11, 2010.
* U1 m2 b3 L( q% z& ?5 s0 e6 O1 g2 WAccepted November 17, 2010. $ S. p" @1 C& g9 f: ^
Abstract# B5 i( k0 D8 q. {$ G4 Y9 J: ^+ ^
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
% T9 J1 S' l0 q- ]/ TPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
2 \  c* B/ _% ^: x/ N$ LResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. * Q8 w8 y& o  G( f
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 1 p1 Q6 n7 D+ k& d2 x; J8 T1 |
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。# o3 G! a/ }& K1 l
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
0 _- ?; y4 D% m; A( T) G% b0 j% x
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
* h$ m+ @) _! c9 S* Ohttp://clinicaltrials.gov/ct2/show/NCT01523587
9 _, t0 i: j' U& ~
, }" n1 k7 p8 V% f5 ~* xBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
4 }! y4 `6 h! m% A4 i* }* ?7 \http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 - t" |( n; W" w. o

( @  B$ \. ?& F& K' |: l* O* o从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
" d/ @  @5 i8 s# X: `至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 6 W) k- D9 c9 l
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。! u, m+ q* T* ?5 r+ ?# `
至今为止,未出 ...
) W! f% B% p8 E3 q* E
没有副作用是第一追求,效果显著是第二追求。9 m6 u* W; Q% b9 A+ S4 Z
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表